Novo Nordisk A/S (NYSE:NVO) Shares Sold by First Dallas Securities Inc.

First Dallas Securities Inc. trimmed its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 48.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,816 shares of the company’s stock after selling 4,499 shares during the period. First Dallas Securities Inc.’s holdings in Novo Nordisk A/S were worth $573,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of NVO. International Assets Investment Management LLC lifted its position in shares of Novo Nordisk A/S by 10,608.4% during the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock valued at $215,942,000 after acquiring an additional 1,796,635 shares during the period. DSM Capital Partners LLC lifted its position in shares of Novo Nordisk A/S by 257,816.0% during the 2nd quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock valued at $227,516,000 after acquiring an additional 1,593,303 shares during the period. Mediolanum International Funds Ltd acquired a new stake in shares of Novo Nordisk A/S during the 3rd quarter valued at approximately $98,765,000. Marshall Wace LLP lifted its position in shares of Novo Nordisk A/S by 34,472.1% during the 2nd quarter. Marshall Wace LLP now owns 691,441 shares of the company’s stock valued at $98,696,000 after acquiring an additional 689,441 shares during the period. Finally, Wellington Management Group LLP acquired a new stake in shares of Novo Nordisk A/S during the 3rd quarter valued at approximately $42,017,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

NVO has been the subject of several research reports. StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. BMO Capital Markets cut their price objective on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Finally, BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. One analyst has rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Buy” and an average price target of $150.40.

Novo Nordisk A/S Trading Up 0.3 %

Shares of NVO opened at $111.10 on Tuesday. The stock has a fifty day moving average of $111.15 and a two-hundred day moving average of $126.90. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The company has a market capitalization of $498.56 billion, a PE ratio of 35.95, a price-to-earnings-growth ratio of 1.41 and a beta of 0.40. Novo Nordisk A/S has a fifty-two week low of $94.73 and a fifty-two week high of $148.15.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.